The FDA approves vutrisiran (Amvuttra) as the first RNAi therapeutic to reduce cardiovascular events and mortality in adults with transthyretin-mediated (ATTR) amyloidosis with cardiomyopathy.
SAHaRA trial investigators compared a liberal (transfusion at hemoglobin levels of 10 g/dL or lower) and a restrictive (transfusion at 8 g/dL or lower) red-cell tranfusion strategy among critically ill patients with acute aneurysmal subarachnoid hemorrhage (SAH) and anemia.
New research links changes in platelet count and volume to aspirin nonresponsiveness in pregnant women who develop preeclampsia, offering insights into potential biomarkers for risk monitoring.
“Tranexamic acid significantly reduced the risk of perioperative bleeding without increasing cardiovascular risk in patients undergoing general surgery procedures,” said Lily J. Park, MD, MSc, and colleagues.